BSX Stock Down -9.2% after 8-Day Loss Streak
Boston Scientific (BSX) stock hit day 8 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -9.2% return. The company has lost about $13 Bil in value over the last 8 days, with its current market capitalization at about $145 Bil. The stock remains 10.0% above its value at the end of 2024. This compares with year-to-date returns of 12.8% for the S&P 500.
BSX provides medical devices for interventional specialties, including diagnostics and treatments for gastrointestinal, pulmonary, urological, pelvic, cardiovascular, rhythm, and neuro conditions. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Sell BSX.
Comparing BSX Stock Returns With The S&P 500
The following table summarizes the return for BSX stock vs. the S&P 500 index over different periods, including the current streak:
- Pay Less, Gain More: BSX, RMD Top IDEXX Laboratories Stock
- With Boston Scientific Stock Sliding, Have You Assessed The Risk?
- Why BSX, RMD Could Outperform IDEXX Laboratories Stock
- Is Boston Scientific’s Bull Thesis Still Intact?
- Boston Scientific Stock To $54?
- BSX, RMD Top IDEXX Laboratories Stock on Price & Potential
| Return Period | BSX | S&P 500 |
|---|---|---|
| 1D | -0.3% | 0.5% |
| 8D (Current Streak) | -9.2% | 2.1% |
| 1M (21D) | -5.3% | 3.4% |
| 3M (63D) | -3.1% | 10.9% |
| YTD 2025 | 10.0% | 12.8% |
| 2024 | 54.5% | 23.3% |
| 2023 | 24.9% | 24.2% |
| 2022 | 8.9% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: BSX Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 51 S&P constituents with 3 days or more of consecutive gains and 36 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 27 | 12 |
| 4D | 17 | 5 |
| 5D | 0 | 17 |
| 6D | 1 | 1 |
| 7D or more | 6 | 1 |
| Total >=3 D | 51 | 36 |
Key Financials for Boston Scientific (BSX)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $14.2 Bil | $16.7 Bil |
| Operating Income | $2.4 Bil | $3.0 Bil |
| Net Income | $1.6 Bil | $1.9 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $4.7 Bil | $5.1 Bil |
| Operating Income | $937.0 Mil | $943.0 Mil |
| Net Income | $674.0 Mil | $797.0 Mil |
The losing streak BSX stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.